Grant: Collaborative Health Research Projects
University of Toronto
$56,256.00
Surface-oriented antibody capture of endothelial progenitor cells for the reduction of post-stent restenosis
FY 2012-13
Summary
Atherosclerosis involves the deposition of plaque on the interior walls of arterial vessels and results in the
narrowing or stenosis of arteries. Although successful, often-used angioplasty suffers from non-uniform arterial
widening and restenosis due to post-surgical recoil of the artery. To mitigate these shortcomings, stenting has
been used as an alternative in suitable candidates. Stents are expandable cylindrical scaffolds that are
implanted within narrowed arteries. They are typically constructed from medical grade stainless steel and can
be implanted as bare metal stents (BMS), or as drug eluting stents (DES) depending on patient candidacy.
Despite the advantages of BMS/DES over angioplasty, their effectiveness remains limited by complications
associated with biocompatibility. For instance, post-stent restenosis due to neointimal hyperplasia (cellular
hypertrophy, proliferation and deposition of extracellular matrix on the stent and around the site of
implantation) remains a significant problem.
In light of the challenges that both BMS and DES face, further research into alternative strategies for the
reduction of both NH and physiological attack of the stent surface is warranted. A promising alternative to
BMS and DES is an antibody-based coating that is capable of capturing endothelial progenitor cells (EPCs).
EPCs are attractive targets for the reduction of NH since they are present in the bloodstream and have been
found to participate in the re-endothelialization of damaged arterial vessels and the inhibition of neointima
formation. An early version of this involves a polymer layer on the device and indiscriminate binding of
protein.
This proposal concerns a new approach for stent surface modification that incorporates control of both the
interfacial population of antibodies, and their correct orientation for optimal binding of EPCs. The Thompson
group has examined the surface chemistry of medical grade stainless steel using atomic force microscopy
(AFM) and x-ray photoelectron spectroscopy (XPS) with a focus on the formation of surface hydroxyl (-OH)
Program
Collaborative Health Research Projects
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
413720-2012
Name nom
Thompson, Michael
Department département
Chemistry (St. George Campus)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2012
Award amount
56256
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
1
Nb partie
3
Application title
Surface-oriented antibody capture of endothelial progenitor cells for the reduction of post-stent restenosis
Keyword
NSERC
Application summary
Atherosclerosis involves the deposition of plaque on the interior walls of arterial vessels and results in the
narrowing or stenosis of arteries. Although successful, often-used angioplasty suffers from non-uniform arterial
widening and restenosis due to post-surgical recoil of the artery. To mitigate these shortcomings, stenting has
been used as an alternative in suitable candidates. Stents are expandable cylindrical scaffolds that are
implanted within narrowed arteries. They are typically constructed from medical grade stainless steel and can
be implanted as bare metal stents (BMS), or as drug eluting stents (DES) depending on patient candidacy.
Despite the advantages of BMS/DES over angioplasty, their effectiveness remains limited by complications
associated with biocompatibility. For instance, post-stent restenosis due to neointimal hyperplasia (cellular
hypertrophy, proliferation and deposition of extracellular matrix on the stent and around the site of
implantation) remains a significant problem.
In light of the challenges that both BMS and DES face, further research into alternative strategies for the
reduction of both NH and physiological attack of the stent surface is warranted. A promising alternative to
BMS and DES is an antibody-based coating that is capable of capturing endothelial progenitor cells (EPCs).
EPCs are attractive targets for the reduction of NH since they are present in the bloodstream and have been
found to participate in the re-endothelialization of damaged arterial vessels and the inhibition of neointima
formation. An early version of this involves a polymer layer on the device and indiscriminate binding of
protein.
This proposal concerns a new approach for stent surface modification that incorporates control of both the
interfacial population of antibodies, and their correct orientation for optimal binding of EPCs. The Thompson
group has examined the surface chemistry of medical grade stainless steel using atomic force microscopy
(AFM) and x-ray photoelectron spectroscopy (XPS) with a focus on the formation of surface hydroxyl (-OH)